奥拉帕尼治疗铂敏感复发性卵巢癌疗效与安全性的Meta分析  

Meta Analysis of Efficacy and Safety of Olaparib in Treating Platinum Sensitive Recurrent Ovarian Cancer

作　　者：王华[1] 都绮月 徐森楠 王昆[2] 吴小枫 张亮亮 邱彦[2,3] 杨嘉永 WANG Hua;DU Qiyue;XU Sennan;WANG Kun;WU Xiaofeng;ZHANG Liangliang;QIU Yan;YANG Jiayong(Huaqiao University Hospital,Huaqiao University,Xiamen 361021,China;School of Medicine,The First Affiliated Hospital of Xiamen University,Xiamen 361003,China;Xiamen Key Laboratory of Chiral Drugs,Xiamen 361100,China;Academy of Advanced Carbon Conversion Technology,Huaqiao University,Xiamen 361021,China;Xiamen Quality Control Center for Comprehensive Pharmaceutical Affairs Management Specialization,Xiamen 361003,China)

机构地区：[1]华侨大学华侨大学医院,福建厦门361021 [2]厦门大学附属第一医院药学部,福建厦门361003 [3]厦门市手性药物重点实验室,福建厦门361100 [4]华侨大学先进碳转化技术研究院,福建厦门361021 [5]厦门市药事综合管理专业质量控制中心,福建厦门361003

出　　处：《华侨大学学报(自然科学版)》2025年第2期223-229,共7页Journal of Huaqiao University(Natural Science)

基　　金：白求恩公益基金“耀动神州药学科研能力建设基金”资助项目(Z04JKM2023E040)。

摘　　要：系统评价奥拉帕尼治疗铂敏感复发性卵巢癌(PSROC)的临床效果及安全性,通过检索公共数据库中的相关研究,收集关于奥拉帕尼与单药化疗/安慰剂治疗PSROC的随机临床试验。应用RevMan 5.3进行Meta分析,最终纳入14篇文献。结果表明:试验组患者的临床缓解率、疾病控制率、无进展生存期均显著优于其他单药化疗药物;试验组患者的消化功能异常、骨髓抑制、神经毒性、心脏毒性及脱发等不良反应发生率显著低于其他单药化疗药物;奥拉帕尼在治疗PSROC方面表现出良好的疗效及较高的安全性。The clinical efficacy and safety of Olaparib in treating platinum sensitive recurrent ovarian cancer(PSROC)were evaluated systematically.The randomized clinical trials on Olaparib and single agent chemotherapy/placebo in the treatment of PSROC were collected by searching relevant studies in public databases.Ultimately,14 articles were incorporated by Meta analysis using RevMan 5.3.The results showed that the clinical remission rate,disease control rate,and progression free survival of patients in the experimental group were significantly better than other single agent chemotherapy drugs.The incidence of adverse reactions such as gastrointestinal dysfunction,bone marrow suppression,neurotoxicity,cardiotoxicity,and alopecia of patients in the experimental group were significantly lower than other single agent chemotherapy drugs.It is indicated that Olaparib shows good efficacy and higher safety in the treatment of PSROC.

关 键 词：奥拉帕尼 铂敏感复发性卵巢癌 临床效果 META分析 

分 类 号：R737.31[医药卫生—肿瘤]